Printer Friendly

R.P. SCHERER STARTS CONSTRUCTION OF NEW FACILITY FOR ITS FAST DISSOLVING DRUG DELIVERY SYSTEMS

 R.P. SCHERER STARTS CONSTRUCTION OF NEW FACILITY
 FOR ITS FAST DISSOLVING DRUG DELIVERY SYSTEMS
 TROY, Mich., March 9 /PRNewswire/ -- R.P. Scherer Corporation (NYSE: SHR) announced today that the first phase of construction work on a new $12 million manufacturing facility for Zydis(R), its rapidly dissolving drug delivery system, has begun. The new plant will be on the same site as Scherer's current Zydis R&D and manufacturing facility, in Swindon, England. It is expected that the new facility will be operational in September of 1993. By the time the second phase of this expansion is completed in 1995, Scherer will have quadrupled its manufacturing capacity for Zydis.
 In further commenting on this announcement, a Scherer spokesman said: "This sizable investment in Zydis reiterates our commitment and belief in the market potential of this proprietary and patented technology. We currently have eight major drugs in various stages of development and regulatory process. Our customers will be using Zydis as one way of protecting their sales from generic competition upon the expiration of their existing patents. Cumulative worldwide sales of these eight drugs in 1991 were in excess of $3 billion. This expansion will enable us to meet anticipated demand associated with these products, as well as the increasing inflow of new development projects."
 R.P. Scherer Corporation, a leading international developer and manufacturer of drug delivery systems, is the world's largest producer of soft gelatin capsules ("softgels"). The company is also currently developing and commercializing advanced drug delivery systems, including the Scherersol(R), Zydis and Pulsincap(TM) technologies. The company's proprietary drug delivery systems improve the efficacy of drugs by regulating their dosage, rate of absorption and place of release. The company operates a global network of 15 facilities in 11 countries.
 -0- 3/9/92
 /CONTACT: Alex Erdeljan of R.P. Scherer Corporation, 313-649-0900/
 (SHR) CO: R.P. Scherer Corporation ST: Michigan IN: MTC SU:


JG -- DE015 -- 6425 03/09/92 12:47 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 9, 1992
Words:327
Previous Article:R.P. SCHERER STARTS CONSTRUCTION OF NEW FACILITY FOR ITS FAST DISSOLVING DRUG DELIVERY SYSTEMS
Next Article:WASSERSTEIN PERELLA APPOINTS JAVIER VEGA DE SEOANE AZPILICUETA SENIOR ADVISER IN SPAIN
Topics:


Related Articles
R.P. SCHERER ANNOUNCES AGREEMENT TO SELL PACO SUBSIDIARY
R.P. SCHERER ANNOUNCES EXPANSION OF ITS NORTH AMERICAN SOFTGEL CAPACITY
R.P. SCHERER STARTS CONSTRUCTION OF NEW FACILITY FOR ITS FAST DISSOLVING DRUG DELIVERY SYSTEMS
SCHERER ANNOUNCES ZYDIS PRODUCT LAUNCH IN ITALY
SCHERER ANNOUNCES AGREEMENT WITH GLAXO
SCHERER ANNOUNCES LAUNCH OF ANOTHER PRODUCT UTILIZING ITS ZYDIS(R) TECHNOLOGY
SCHERER ANNOUNCES LAUNCH OF ANOTHER PRODUCT UTILIZING ITS ZYDIS TECHNOLOGY
SCHERER OPENS NEW ZYDIS MANUFACTURING FACILITY
R.P. SCHERER REPORTS NDA FILING FOR CLARITIN ZYDIS
Scherer Announces U.S. Marketing Clearance for the First Prescription Product Using Zydis(R) Technology

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters